PUSHING THE FRONTIERS OF RADIOBIOLOGY: A SPECIAL FEATURE IN MEMORY OF SIR OLIVER SCOTT AND PROFESSOR JACK FOWLER: REVIEW ARTICLE

The tumour microenvironment links complement system dysregulation and hypoxic signalling

MONICA M OLCINA, RYAN K KIM, STAVROS MELEMENIDIS, EDWARD E GRAVES and AMATO J GIACCIA

Department of Radiation Oncology, Stanford University, Stanford, CA, USA

Address correspondence to:
Dr Monica M Olcina
E-mail: molcina@stanford.edu
Amato J Giaccia
E-mail: giaccia@stanford.edu

ABSTRACT

The complement system is an innate immune pathway typically thought of as part of the first line of defence against “non-self” species. In the context of cancer, complement has been described to have an active role in facilitating cancer-associated processes such as increased proliferation, angiogenesis and migration. Several cellular members of the tumour microenvironment express and/or produce complement proteins locally, including tumour cells. Dysregulation of the complement system has been reported in numerous tumours and increased expression of complement activation fragments in cancer patient specimens correlates with poor patient prognosis. Importantly, genetic or pharmacological targeting of complement has been shown to reduce tumour growth in several cancer preclinical models, suggesting that complement could be an attractive therapeutic target. Hypoxia (low oxygen) is frequently found in solid tumours and has a profound biological impact on cellular and non-cellular components of the tumour microenvironment. In this review, we focus on hypoxia since this is a prevailing feature of the tumour microenvironment that, like increased complement, is typically associated with poor prognosis. Furthermore, interesting links between hypoxia and complement have been recently proposed but never collectively reviewed. Here, we explore how hypoxia alters regulation of complement proteins in different cellular components of the tumour microenvironment, as well as the downstream biological consequences of this regulation.

INTRODUCTION

The tumour microenvironment is composed of a complex set of immune and non-immune components. Together the components of the tumour microenvironment promote a pro-tumorigenic milieu by secreting pro-inflammatory molecules as well as growth factors and extracellular matrix degrading enzymes. Complement is an innate immune component of the tumour microenvironment that has received increasing attention in recent years. Complement has typically been regarded as a set of soluble and membrane-bound proteins involved in the first line of defence against pathogenic organisms. Almost all immune cell types have been found to express complement proteins and importantly tumour and stromal cells may also produce several complement factors. The exact details underlying the complex regulation of complement activation in the tumour microenvironment are not completely understood but elegant studies have highlighted that high levels of complement activation products as well as regulators in cancer cells often are associated with decreased prognostic outcome.

“Non-cellular” factors in the tumour microenvironment can also have a negative impact on patient prognosis and are involved in regulating the biological behaviour of the different components of the tumour microenvironment, including complement. A clear example of a prevalent “non-cellular” factor of the tumour microenvironment, pervasive amongst almost all solid tumours, is hypoxia. Tumour hypoxia refers to the low oxygen tensions that arise due to the imbalance between oxygen supply and demand in the aberrantly-perfused tumour. Hypoxia is well known to influence several cellular and pro-tumorigenic components of the tumour microenvironment.
this review we describe how the impact of hypoxia on cellular members of the tumour microenvironment affects complement regulation and how complement dysregulation can contribute to tumour progression. A detailed description of cells associated with the tumour microenvironment is outside the scope of this review and has been described elegantly by Hanahan and Coussens. Instead, focus will be placed on those components of the tumour microenvironment that are well known to be influenced by hypoxia.

The complement system in cancer
The complement system is a network of soluble serum proteins, membrane-bound receptors and regulatory proteins that interacts with both innate and adaptive immune system effectors. Complement serves as an intermediary between the two branches of the immune system to eliminate pathogens or “altered-self” by opsonisation, inflammatory response mounting and direct cell lysis. Opsonisation refers to the process of tagging of altered species leading to engulfment by phagocytes. There are three major pathways to complement activation: classical, lectin and alternative, each of which is initiated by different signalling stimuli but converges at the downstream cleavage of complement component 3 (C3) to produce C3a and C3b (Figure 1). C3b production facilitates formation of the C5 convertase which cleaves C5 into C5a and C5b, the latter of which initiates assembly of the membrane attack complex (MAC) on the cell membrane leading to lysis. The classical pathway is initiated by recognition of immune complexes while the lectin pathway is initiated by recognition of carbohydrates or glycans on the pathogen’s surface, resulting in the convergence of the two pathways with cleavage of C2 and C4 to generate C2a, C2b, C4a and C4b. C2a and C4a remain soluble to act as inflammatory mediators while C2b and C4b form the C3 convertase C4b2b. C3 is then cleaved by C4b2b to generate anaphylatoxin C3a and C3b. C3b can serve as an opsonin, or, upon binding with the C3 convertase, forms the C5 convertase C4b2b3b. C5 is then cleaved producing C5a and C5b. C5a is another potent inflammatory mediator while C5b initiates MAC formation and results in cytolytic activity. The alternative pathway can be initiated by (a) spontaneous hydrolysis of soluble C3 producing C3(H2O), or (b) non-covalent binding of properdin to the target membrane. C3(H2O) binds with Factor B and Factor D which cleaves Factor B into Ba and Bb. C3(H2O) and Bb form one of the alternative pathway C3 convertases. Properdin binds with C3b and Factor B, cleaving Factor B to produce the alternative pathway C3 convertase C3bBb. C3 cleavage is amplified in the alternative pathway and accounts for approximately 70% of complement activity. The C3 convertase C3bBb binds with another C3b fragment forming the alternative pathway C5 convertase C3bBb3b.6–8,17,18 MAC, membrane attack complex.
pathogen’s surface, thereby lysing the cell by perforating the cell membrane (Figure 1). C5a is the most potent anaphylatoxin of the complement system, 20-fold more potent than C3a and 2500-fold more than C4a. Anaphylaxis can induce inflammation and lead to secretion of IL-6 and TNF-α. Anaphylaxis can also result in promotion of phagocytosis, and movement of lymphocytes into neighbouring lymph nodes. The effects of complement are tightly regulated by complement regulatory proteins which serve to accelerate degradation of complement components and convertases as well as inhibit MAC formation (Figure 2).

Despite the defensive capabilities of the complement system, only limited evidence has demonstrated direct complement-mediated elimination of nascent tumours. However, tumours have been found to exhibit complement-avoidance mechanisms, indirectly supporting a tumour-suppressive role for complement during cancer initiation. The expression of complement regulators is upregulated in a variety of cancer types which suggests a selective pressure in favour of protection against complement recognition and complement-mediated attack. Additionally, levels of complement activation fragments are upregulated in cancer patients suggesting that recognition of tumours by immune complexes triggers complement activation.

Complement also has an immunomodulatory role in potentiating the responses of other immune cells involved in immunosurveillance and other tumour defence mechanisms. Complement activation can enhance adaptive immune responses by enhancing dendritic cell uptake, antigen presentation and lowering the threshold for B cell activation. Other studies have shown that the presence of complement receptors for C3a and C5a (C3aR and C5aR1) are involved in CD4+ T-cell survival and differentiation. In this context, complement activity has been shown to contribute to cancer vaccine responses with promising results.
However, the canonical understanding of complement acting solely as a protective system has been challenged by a growing body of evidence showing that complement activation may also promote tumourigenesis. Notably, in a murine model of colitis-associated colon cancer using azoxymethane and dextran sulphate sodium, loss of complement proteins C3, C3aR1 and C5aR1 was found to suppress tumourigenesis formation. The authors proposed that C5a-dependent induction of the IL-1β/IL-17A signalling axis was responsible for this effect. The link between inflammation and tumour progression is well recognised, and the fact that complement is upregulated in patients with cancer may allow nascent tumours to productively use anaphylatoxin-induced inflammation. Furthermore, C3aR and C5aR1 signal through the PI3K-AKT pathway in an autocrine manner thereby facilitating tumour cell proliferation. Complement system activation within the tumour microenvironment therefore has a multitude of roles. While the canonical defensive capabilities of complement-mediated attack were originally hypothesised to facilitate immune detection and clearance of tumours, a growing body of evidence suggests that increased expression of complement proteins is typically associated with poor prognosis and likely serves tumour promoting roles. Significantly, the interest in targeting complement either alone or in combination with other therapies warrants a more exhaustive study of the complexities underlying complement system regulation in the tumour microenvironment.

Complement

**Hypoxia in the tumour microenvironment**

Hypoxia, an oxygen deficiency in tissues, is a common feature of the tumour microenvironment. Hypoxia usually exists as a range of O₂ concentrations typically ranging from 2 to <0.1% in tumours as opposed to 9–5 to 1% in normal tissues. Tumour hypoxia is often classified as either acute or chronic, both types typically originating as a consequence of the disorganised, inefficient and torturous tumour vasculature. Acute hypoxia, for instance, can occur due to temporary blood flow shutdown following obstruction of vessels. Chronic hypoxia can occur for several reasons, including cell proliferation beyond the oxygen diffusion distance from tumour microvessels. The low oxygen state results in pro-survival gene expression changes that result in a plethora of effects including increased tumour angiogenesis, invasion and metastasis. Consequently, hypoxia correlates with a negative patient prognosis. Furthermore, hypoxia is associated with reduced effectiveness of several treatments including radiotherapy. Many of these changes are driven by a family of transcription factors called the hypoxia-inducible factors (HIFs). Though there are several different HIF isoforms, HIF-1 has been the primary target for study in gene expression alterations associated with cancer. HIF-1 is a heterodimer that consists of a constitutively expressed HIF-1β subunit and a more tightly regulated HIF-1α subunit. Under normoxic conditions, HIF-1α is targeted for degradation via oxygen-dependent degradation that involves hydroxylation and ubiquitination leading to proteolysis of the subunit. In hypoxic conditions, HIF-1α is not ubiquitinated and is able to interact with the beta subunit, forming the heterodimer. This occurs because of the oxygen sensitivity of prolyl hydroxylase domain containing proteins (PHDs) which hydroxylate two residues on HIF-1α, P402 and P564, which are necessary for von Hippel-Lindau disease tumour suppressor binding and ubiquitination. PHDs have a relatively high Km value of 230–250 μM for oxygen, ensuring that given adequate levels of other substrates and cofactors, oxygen is the controlling factor in PHD activity. A functional HIF complex binds to hypoxia-responsive elements and induces the expression of a number of genes that alter the cell’s ability to adapt to the low oxygen environment.

Besides cancer cells, the tumour microenvironment is composed of stromal cells, including cancer-associated fibroblasts, immune cells, endothelial cells and pericytes. Hypoxia affects the biological responses of all of these tumour microenvironment cells in a manner that usually potentiates tumour progression. For example, hypoxia within the tumour microenvironment stimulates HIF-dependent angiogenesis through recruitment of endothelial cells and pericytes. This process also enables recruitment of bone marrow derived cells. Growth factor signalling coupled with extracellular matrix remodelling by recruited stromal cells can further facilitate tumour progression.

Hypoxic regulation of the complement system in tumour cells

Regulation of both complement component and regulator proteins has been described in tumour cells exposed to hypoxia (Figure 3). Early reports indicated that hypoxia-induced messenger RNA (mRNA) expression of central complement component C3 in liver cancer (HepG2) cells. Non-small cell lung cancer cells exposed to hypoxia (1% O₂) have more recently been described to express reduced levels of complement regulators CD46, CD55 and CD59. Decreased secretion of factor I and factor H was also reported in non-small cell lung cancer cells exposed to hypoxia. The authors of this study hypothesised that altered levels of complement regulators under hypoxic conditions could lead to changes in complement-mediated lysis since increased C3b and C9 deposition coincided with altered expression of complement regulators. However, no significant changes in complement-mediated attack were reported.

Interestingly, the use of antigens used/produced during immunodetection of tumour hypoxia when 2-nitroimidazoles (e.g. pimonidazole) bind to hypoxic cells has been proposed as a means of stimulating complement-mediated lysis of tumour cells. This hypothesis was tested using rabbit complement as a means of lysing pimonidazole-labelled V79-4 cells in the presence of monoclonal antibody recognising reductively activated pimonidazole protein adducts. In this system, the authors reported complement-mediated lysis of tumour cells at pimonidazole concentrations below those known to affect cell viability. It would be interesting to test this concept in vivo to assess the
Interplay between complement and cellular components of the tumour microenvironment

Interplay between complement and cellular components of the tumour microenvironment

T-cells

Increasing interest in the study of hypoxic regulation of T-cell function has highlighted the complexity of the effects of hypoxia and hypoxic signalling on this cell population. While low oxygen concentrations have been reported to increase CD8+ T-cell cytotoxicity, hypoxia can also decrease the production of effector and proliferative cytokines in T-cells. Interestingly, a major impact of hypoxia on T-cell function stems from the metabolic changes associated with hypoxic environments resulting in an acidic pH. For instance, T-cell proliferation induced by IL-2 is arrested at pH 6.7. This is a problem in hypoxic tumours which can typically have an extracellular pH range of 5.8–6.5. Overall, the effects of hypoxia on T-cell function and survival can therefore probably be considered to contribute to the development of an immunosuppressive microenvironment. With respect to complement, a number of recent elegant studies have highlighted how complement activation in the tumour microenvironment further contributes to the immunosuppressive phenotype. C3 was recently found to have an inhibitory effect on CD8+ T-cells through IL-10 inhibition. Increased IL-10 expression in C3-deficient mice renders mice resistant to tumour development in a IL-10- and T-cell-dependent manner. C5a further leads to a decrease in cytotoxic CD8+ T-cell responses through recruitment of myeloid-derived suppressor cells (MDSCs). Increased T-cell suppressive capabilities are associated with C5a-mediated regulation of reactive oxygen and nitrogen species in MDSCs. Hypoxia also regulates reactive nitrogen species through hypoxic induction of inducible nitric oxide synthase which increases reactive nitrogen species, especially peroxynitrite. Increased reactive nitrogen species have a number of consequences, including nitration of CCL2 which diminishes effector lymphocyte recruitment function while retaining suppressive myeloid cell chemo-attractant capabilities.

Macrophages

Macrophages recognise "molecular patterns" on the surfaces of pathogens in a process involving multiple ligand-receptor interactions. Opsonins such as complement component cleavage products play an important role in this process by orchestrating pathogen internalisation during phagocytosis. Links between complement activation and tumour promoting macrophage recruitment have been established in the context of PTX3 deficiency, which leads to complement activation and increased CCL2 production. Importantly these phenotypes are associated with increased susceptibility to certain mesenchymal and epithelial tumours. The PTX3 gene is silenced by methylation in certain cancers further increasing the clinical relevance of the association between complement regulation and macrophage recruitment.
C3a and C5a receptors are expressed on the cell surface of macrophages and the binding of ligands for these receptors has also been suggested to modulate angiogenesis.7,86 The association between complement components and macrophage polarisation has also been suggested to correlate with hypoxic signaling (Figure 4). Hypoxia and HIF-signalling are indeed critical for macrophage polarisation and deletion of either HIF-1α or 2α in macrophages reduces tumour growth.74,87

Neutrophils
Recruitment of immune cells such as neutrophils and monocytes can result in induction of hypoxia at sites of inflammation.91 Hypoxia has indeed been associated with inflammatory conditions, some of which have been proposed to predispose to cancers. This is the case for colitis and inflammatory bowel disease.92-94 In these inflammatory conditions, transepithelial migration of neutrophils is a marker of mucosal inflammation.95 Several proteins are implicated in the interaction between neutrophils and epithelial cells including complement regulator CD55. CD55 functions in the later stages of transepithelial migration by facilitating the release of neutrophils from the epithelial surface.96 CD55 is expressed on the apical membrane of mucosal epithelial cells. Importantly, HIF-binding sites are found in CD55 and CD55 expression was found to be hypoxia inducible (Figures 3 and 4).97 Therefore, hypoxia, through CD55 induction, may enhance neutrophil transepithelial migration and promote neutrophil clearance from the epithelial surface in conditions predisposing to cancer.97

A further role for complement in neutrophil function has been described in melanoma where C3a/C3aR1 signalling has been implicated in tumour progression by inhibiting CD4+ T-cell and neutrophil responses.88 C3aR1 was also found to be upregulated in intestinal neutrophils in a murine model of intestinal tumourigenesis (using APCmin/+ mice), where C3aR1 signalling promoted tumourigenesis through triggering neutrophil extracellular traps.98

Endothelial cells
Endothelial cells are critical for angiogenesis, the process of new capillary growth from established blood vessels. Angiogenesis is important for nutrient and oxygen supply and is a process induced following periods of hypoxia.44,45 Whether or not complement activation promotes or inhibits angiogenesis is controversial and seems to depend on the model and disease being studied.9 Some of the controversy may stem from the dual role described for some complement proteins expressed on endothelial cells. CR1 for example has been found to be expressed in primary human umbilical vein endothelial cells (HUVECs) and hypoxia (1% O2) induces CR1 protein expression.99 CR1 is both a receptor for C1q and a regulator of the complement system suggesting that hypoxic induction of CR1 could have positive or negative effects.
on complement activation on these cells. Interestingly, CR1 in HUVECs was found to be present intracellularly and could act as a cofactor for factor I-mediated cleavage of C3b to C3c and C3dg. soluble CR1 on the other hand was found to inhibit binding of C3b and immune complexes to hypoxic HUVECs and it was suggested that a portion of CR1 is expressed on the extracellular membrane. A recent study reported C1q expression in the stroma and vascular endothelium of tumours correlating with increased vascular density and lung metastasis. Importantly, B16 melanoma tumours display decreased tumour growth in C1q-deficient mice and these effects were not attributed to differences in immune cell infiltration.

Classical complement activation has also been proposed to occur on endothelial cells following hypoxia/reoxygenation in vitro. Most of these studies have used HUVECs exposed to hypoxia (1% O2) or hypoxia followed by reoxygenation at 21% O2 as a model of hypoxia/reoxygenation to exposed to ischaemia reperfusion injury. During initial studies, complement activation was found to occur in the presence of serum-activated complement. Interestingly, reoxygenation-induced complement activation was subsequently shown to be inhibited by membrane permeable free radical scavengers. Intriguingly, surface expression of complement regulators CD55 and CD46 was also found to be increased in early studies. Furthermore, a subsequent study reported that C3d deposition in this model was thought to occur on reoxygenated apoptotic cells and this appeared to occur in the absence of antibodies or serum factors. In support of these findings C3 activation was abolished after treatment with caspase inhibitor treatment. It would be interesting to investigate if complement is also activated on other cells in the tumour microenvironment following the induction of apoptosis (either during reoxygenation or following treatment with apoptosis inducing agents such as chemotherapeutic agents paclitaxel). With the increasing interest in immune checkpoint inhibitors, the potential for targeting complement, particularly at the level of C5a/C5AR axis, together with current immunotherapy approaches, such as programmed death 1/programmed death ligand 1 (PD-1/PD-L1) antibodies, has been explored. Interestingly, increased complement activation, including, C5a was found to be produced in tumours following treatment with anti-PD-1 antibodies. Remarkably, however, increased anti-tumour immunity following complement inhibition (such as with C5aR1 antagonists) was found to be independent of the PD-1/PD-L1 immune checkpoint pathway. These findings have led to the suggestion that complement receptors such as C5aR1 and C3aR1 could be a new class of immune checkpoints to be targeted.

Furthermore, it has been found that radiotherapy elicits C3a and C5a upregulation within the tumour microenvironment, potentially aiding in the anti-tumour response. However, seemingly contradictory results have been published as it was shown that complement inhibition enhances anti-tumour response after fractionated radiation therapy.

CONCLUSION
Complement activation and hypoxia have both been shown to facilitate tumour progression by altering the function of tumour microenvironment components. Complement-effector functions alter cellular components known to be modulated by hypoxia such as tumour cells, endothelial cells, T-cells, macrophages and neutrophils. Interestingly, complement imbalances in these cells have also been associated with hypoxia-associated processes such as increased migration, angiogenesis and immunomodulation. Hypoxia has been directly shown to alter regulation of complement proteins not only in cancer cells but also in endothelial cells. It is tempting to speculate that hypoxia-mediated regulation of complement in other cellular components such as T-cells, macrophages and MDSCs might be described in the future given the already established links between these cell types and complement. T-cells, macrophages and MDSCs have emerged as critical immune components of the tumour microenvironment so any potential interplay between hypoxia and complement in these cells could have important biological consequences for tumour progression.

Importantly, targeting both hypoxia (and hypoxia-associated processes) as well as complement has been proposed as a means of improving tumour responses both from an immune and non-immune standpoint. It would be interesting to explore whether targeting both complement and hypoxia might yield improved clinical responses.

ACKNOWLEDGEMENTS
We would like to apologise to all the excellent work that we were not able to reference in this study due to space limitations. We would also like to thank Servier Medical Art for the their images.

FUNDING
This work was supported by NIH Grants CA-67166 and CA-197713, the Silicon Valley Foundation, the Sydney Frank
REFERENCES

1. LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol 2016; 18: 356–65 . doi: https://doi.org/10.1038/ncb3330
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309–22 . doi: https://doi.org/10.1016/j.ccr.2012.02.022
3. Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 2014; 14: 430–9 . doi: https://doi.org/10.1038/nrc3726
4. Rosfjord EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000; 76: 589–605 . doi: https://https://doi.org/10.1080/09550674(91)9126495
5. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the complement cascade. Mol Cancer Res 2010; 8: 1453–65 . doi: https://https://doi.org/10.1158/1541-7786.MCR-10-0225
6. Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. Complement in cancer: untangling an intricate relationship. Nat Rev Immunol 2018; 18: 5–18 . doi: https://https://doi.org/10.1038/nri.2017.97
7. Sayegh ET, Bloch O, Parsa AT. Complement anaphylatoxins as immune regulators in cancer. Cancer Med 2014; 3: 747–58 . doi: https://https://doi.org/10.1002/cam4.241
8. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Rev Immunol 2011; 11: 393–410 . doi: https://https://doi.org/10.1038/nri3064
9. Mak TW, Saunders ME. Ch 4 Inmate Immunity. In: The immune response; 2006. pp. 69–92.
10. Tegla CA, Cudrici C, Patel S, Trippe R, Rusowski MT. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Rev 2011; 251: 41–60 . doi: https://https://doi.org/10.1111/j.1600-065X.2010.01191.x
11. Moon EJ, Brintz DM, Chi J–T, Dewhurst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007; 9: 1237–94 . doi: https://https://doi.org/10.1089/ars.2007.1623
12. Aebersold DM, Burri P, Beer KT, Laisse J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1a: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911–6.
13. Dendy PP, Wardman P. Hypoxia in biology and medicine: the legacy of L H Gray. Br J Radiol 2006; 79: 545–9 . doi: https://https://doi.org/10.1259/bjr/13634453
14. Pio R. Control of complement activation by cancer cells and its implications in antibody-mediated cancer immunotherapy. Immunolog 2006; 25: 173–87.
15. Magotti P, Ricklin D, Qu H, Wu Y-Q, Kazzessis YN, Lambris JD, et al. Structure–kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J Mol Recognit 2009; 22: 495–505 . doi: https://https://doi.org/10.1002/jmr.972
16. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393–410 . doi: https://https://doi.org/10.1038/nrc3064
17. Mak TW, Saunders ME. Ch 4 Inmate Immunity. In: The immune response; 2006. pp. 69–92.
18. Tegla CA, Cudrici C, Patel S, Trippe R, Rusowski MT. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Rev 2011; 251: 41–60 . doi: https://https://doi.org/10.1111/j.1600-065X.2010.01191.x
19. Gros P, Milder FJ, Jansen BJ. Complement driven by conformational changes. Nat Rev Immunol 2008; 8: 48–58 . doi: https://https://doi.org/10.1038/nri2231
20. Peitsch MC, Tschopp J. Assembly of proinflammatory molecule? re-evaluating complement activation product C3a a anaphylatoxin. Anaphylatoxins as immune regulators in complement. Clin Exp Immunol 2009; 2012: 234–41 . doi: https://https://doi.org/10.1046/j.1365-2249.2000.01305.x
21. Kapka-Skrzypczak L, Wolinska E, Szparecki G, Wilczynski GM, Czajka M, Skrzypczak M, et al. Membrane-bound complement regulatory proteins (mCRPs) in tumors. In: Molecular Immunology; 2003. pp. 109–23.
22. Yan J et al. The role of membrane complement regulatory proteins in cancer immunotherapy. In: Current Topics in Complement II; 2009. pp. 152–67.
23. Peitsch MC, Tschopp J. Assembly of proinflammatory molecule? re-evaluating complement activation product C3a as an anaphylatoxin. Anaphylatoxins as immune regulators in complement. Clin Exp Immunol 2009; 2012: 234–41 . doi: https://https://doi.org/10.1046/j.1365-2249.2000.01305.x
24. Kapka-Skrzypczak L, Wolinska E, Szparecki G, Wilczynski GM, Czajka M, Skrzypczak M, et al. Membrane-bound complement regulatory proteins (mCRPs) in tumors. In: Molecular Immunology; 2003. pp. 109–23.
25. Lackner Z, Donin N, Zell S, Schultz S, Kirschkink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. In: Molecular Immunology; 2003. pp. 109–23.
26. Fishelson Z, Donin N, Zell S, Schultz S, Kirschkink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. In: Molecular Immunology; 2003. pp. 109–23.
27. Spiller OB, Criado-Garcia O, Rodriguez De Còrdoba S, Morgan BP. Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol 2009; 2012: 234–41 . doi: https://https://doi.org/10.1046/j.1365-2249.2000.01305.x
28. Oktay M, Corrales L, Stokowska A, Pio R, Blom AM. Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol. Immunother 2009; 58: 1771–80 . doi: https://https://doi.org/10.1007/s00262-009-0683-8
29. Kapka-Skrzypczak L, Wolinska E, Szparecki G, Wilczynski GM, Czajka M, Skrzypczak M, et al. CD55, CD59, factor H and factor I-like 1 gene expression analysis in tumors of the ovary and corpus uteri origin. Immun Lett 2015; 167: 67–71 . doi: https://https://doi.org/10.1016/j.imlet.2015.06.017
30. Nishioka K, Kasaemura K, Hirayama T, Kawashima T, Shimada K, Kogure M, et al. The complement System in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann N Y Acad Sci 1976; 276: 303–15 . doi: https://https://doi.org/10.1111/j.1749-6632.1976.tb41656.x
31. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity 2012; 37: 199–207 . doi: https://https://doi.org/10.1016/j.immuni.2012.08.002
32. Schmudde I, Laumonnier Y, Köhl J. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin Immunol 2013; 25: 2–11 . doi: https://https://doi.org/10.1016/j.smim.2013.04.009

Foundation and the Kimmelman Fund (AJG). MMO is a Cancer Research Institute Irvington Fellow supported by the Cancer Research Institute. RKK was supported by Stanford ChEM-H Undergraduate Scholars Program.
33. Dunkelberger JR, Song W-C. Complement and its role in innate and adaptive immune responses. Cell Res 2010; 20: 34–50. doi: https://doi.org/10.1038/cr.2009.139

34. Fang Y, Xu C, YX F, Holers VM, Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 1998; 160: 5273–9.

35. Freeley S, Kemper C, Le Friec G. The "ins and outs" of complement-driven immune responses. Immunol Rev 2016; 274: 16–32. doi: https://doi.org/10.1111/imr.12472

36. Liszewski MK, Kolev M, Le Friec G, Hammond EM, Asselin M-C, Forster D, and others. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Clin Invest 2001; 108: 39–40. doi: https://doi.org/10.1172/JCI13374

37. Ning C, Li Y-Y, Wang Y, Han G-C, Wang X, et al. The “ins and outs” of complement-driven immune responses. Immunol Rev 2016; 274: 16–32. doi: https://doi.org/10.1111/imr.12472

38. Bonavita E, Gentile S, Rubino M, Maina O’Connor JPB, Senra JM, Williams KJ, and others. The concentration of oxygen dissolved in tissues at the time of irradiation dissolved in tissues at the time of irradiation. Br J Radiol;92:20180069

39. Bussink J, Kaanders JHAM, van der Kogel AJ. Hypoxia, gene expression, and metastasis. Cancer Metab 2012; 3: 3. doi: https://doi.org/10.1186/2049-3002-3-2

40. Cho MS, Vasquez HG, Rupaimoo R, Pradeep S, Wu S, Zand B, et al. Autocrine effects of tumor-derived complement. Cell Rep 2014; 6: 1085–95. doi: https://doi.org/10.1016/j.celrep.2014.02.014

41. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638–48. doi: https://doi.org/10.1016/0014-9286(53)90259-9

42. Hammond EM, Asselin M-C, Forster D, O’Connor JPB, Senra JM, Williams KJ, and others. The concentration of oxygen dissolved in tissues at the time of irradiation. Br J Radiol;92:20180069

43. Bayer C, Shi K, Astner ST, Mafett C-A, Vaupel P. Acute versus chronic hypoxia: Why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys 2011; 80: 965–8. doi: https://doi.org/10.1016/j.ijrobp.2011.02.049

44. Semenza GL. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J Clin Invest 2001; 108: 39–40. doi: https://doi.org/10.1172/JCI13374

45. Bussink J, Kaanders JHAM, van der Kogel AJ. Hypoxia, gene expression, and metastasis. Cancer Metab 2012; 3: 3. doi: https://doi.org/10.1186/2049-3002-3-2

46. Rankin EB, Giaccia AJ. Hypoxia control of metastasis. Science 2016; 352: 175–80. doi: https://doi.org/10.1126/science.aaf4405

47. Masson N, Ratcliffe PJ. Hypoxia, gene expression, and metastasis. JCI13374

48. Vaupel P, Thews O, Hockel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001; 18: 243–59. doi: https://doi.org/10.1007/s10555-007-9063-1

49. Hammond EM, Olicna M, Giaccia AJ. Hypoxia and modulation of cellular radiation response. Berlin: Springer; 2011.

50. Okuda Tel et al. Hypoxia-inducible factor 1 and vascular endothelial growth factor overexpression in ischemic colitis. World J Gastroenterol 2005; 11: 1535–9. doi: https://doi.org/10.3748/wjg.v11.i10.1535

51. Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab 2014; 2: 3. doi: https://doi.org/10.1186/2049-3002-2-3

52. Okuda Tel et al. Hypoxia-inducible factor 1 and vascular endothelial growth factor overexpression in ischemic colitis. World J Gastroenterol 2005; 11: 1535–9. doi: https://doi.org/10.3748/wjg.v11.i10.1535

53. Goonewardene TI, Sowter HM, Harris AL. Hypoxia-induced pathways in breast cancer. Microsc Res Tech 2002; 59: 41–8. doi: https://doi.org/10.1002/jemt.10175

54. Olicna MM, Kim R, Giaccia AJ. The role of hypoxia in radiation response. Berlin: Springer; 2016.

55. Greer SN, Metcalf JL, Wang Y, Ohh M. The updated biology of hypoxia-inducible factor. EMBO J 2012; 31: 2488–60. doi: https://doi.org/10.1038/emboj.2012.125

56. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92: 5510–4. doi: https://doi.org/10.1073/pnas.92.12.5510

57. Pugh CW, O’Rourke JF, Nagao M, Gleddie JM, Ratcliffe PJ. Activation of hypoxia-inducible factor-1: Definition of regulatory domains within the α subunit. J Biol Chem 1997; 272: 11205–14. doi: https://doi.org/10.1074/jbc.272.17.11205

58. Jaakkola P, Moel DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, and others. Targeting of HIF-α to the von Hippel-Lindau ubiquitination complex by O2-regulated prolyl hydroxylase. Science 2001; 292: 468–72. doi: https://doi.org/10.1126.science.1059796

59. Ivan M, Kondo K, Yang H, Kim W, Valianti J, Ohh M, and others. HIFα targeted for VHL-mediated destruction by proline hydroxylases: implications for O2 sensing. Science 2001; 292: 464–8. doi: https://doi.org/10.1126/science.1059817

60. Chan DA, Sutphin PD, Yen SE, Giaccia AJ. Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1α. Mol Cell Biol 2005; 25: 6415–26. doi: https://doi.org/10.1128/MCB.25.15.6415-6426.2005

61. Epstein AC, Gleddie JM, McNell LA, Hewitson KS, O’Rourke J, Moel DR, and others. HIFα regulates the oxygen-dependent degradation domains of hypoxia-inducible factor 1α. Mol Cell Biol 2005; 25: 4997–5006. doi: https://doi.org/10.1128/MCB.25.15.6415-6426.2005

62. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001; 294: 337–40. doi: https://doi.org/10.1126/science.1066373

63. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Günzler V, Kondo K, and others. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A 2002; 99: 13459–64. doi: https://doi.org/10.1073/pnas.192342099

64. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, and others. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271–5. doi: https://doi.org/10.1038/20459

65. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 by the von Hippel-Lindau tumor suppressor protein. Embo J 2000; 19: 4298–309. doi: https://doi.org/10.1093/emboj/19.16.4298

66. Fong GH, Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ 2008; 15: 635–41. doi: https://doi.org/10.1038/cdd.2008.10
76. Caldwell CC, Kojima H, Lukashev D, et al. Hypoxia-inducible factor-1 protects in murine experimental colitis. J Clin Invest 2004; 114: 1098–106. doi: https://doi.org/10.1172/JCI200421086

77. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999; 17: 593–623. doi: https://doi.org/10.1146/annurev.immunol.17.1.593

78. Underhill DM. Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 2002; 20: 825–52. doi: https://doi.org/10.1146/annurev.immunol.20.103001.114744

81. Tan S, Zhou F, Nielsen VG, Wang Z, et al. Hypoxia-induced expression of macrophage receptors and immune recognition. Annu Rev Immunol 2005; 23: 901–44. doi: https://doi.org/10.1146/annurev.immunol.23.021704.151861

82. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilko S, Avella D, et al. Chemokine nitrination prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208: 1949–62. doi: https://doi.org/10.1084/jem.20101956

83. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol 2001; 19: 573–602. doi: https://doi.org/10.1146/annurev.immunol.19.1.573

84. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999; 17: 593–623. doi: https://doi.org/10.1146/annurev.immunol.17.1.593

85. Underhill DM, Ozinsky A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 2002; 20: 825–52. doi: https://doi.org/10.1146/annurev.immunol.20.103001.114744

86. Langer HF, Chung K-J, Orlova VV, Choi EY, Kaul S, Kruhlak MJ, et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 2010; 116: 4395–403. doi: https://doi.org/10.1182/blood-2010-01-261503

87. Imtiyaz HZ, Williams EP, Hickey MM, Patel SA, Durham AC, Yuan J-L, et al. Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 2010; 120: 2699–714. doi: https://doi.org/10.1172/JCI9506

88. Nabizadeh JA, Manthey HD, Steyn FI, Chen W, Widjapradja A, Md Akhir FN, et al. The complement C3a receptor contributes to melanoma tumorigenesis by inhibiting neutrophil and CD4+ T cell responses. J Immunol 2016; 196: 4783–92. doi: https://doi.org/10.4049/jimmunol.1600210

89. Collard BD, Bukoskog C, Agah A, Colgan SP, Reenstra WR, Morgan BP, et al. Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. Am J Physiol Cell Physiol 1999; 276–C450–C458. doi: https://doi.org/10.1152/ajpcell.1999.276.2.C450

90. http://smart.servier.com/. Accessed 2/26/2018.

91. Karhausen J, Haase VH, Colgan SP. Inflammatory hypoxia: role of hypoxia-inducible factor. Cell Cycle 2005; 4: 255–7. doi: https://doi.org/10.1089/cc.4.2.1407

92. Kruiswijk MS, Fottikz T, Perez-Cantó A, Hübberger A, Buhr JH. Changes of colonic mucosal microcirculation and histology in two colitis models: an experimental study using intravital microscopy and a new histological scoring system. Dig Dis Sci 2001; 46: 2363–43. doi: https://doi.org/10.1023/A:1012334725909

93. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004; 114: 1098–106. doi: https://doi.org/10.1172/JCI200421086

94. Hatoum OA, Rinnion DG, Ottersen MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125: 58–69. doi: https://doi.org/10.1053/j.gastro.2003.06.030

95. Jaye DL, Parkos C. A. Neutrophil migration across intestinal epithelium. Ann N Y Acad Sci 2000; 915: 151–61. doi: https://doi.org/10.1111/j.1749-6632.2000.tb05288.x

96. King PD, Batchelor AH, Lawlor P, Katz DR. The role of CD44, CD45, CD45RO, CD46 and CD55 as potential anti-adhesion molecules involved in the binding of human tonsillar T cells to phorbol 12-myristate 13-acetate-differentiated U-937 cells. Eur J Immunol 1990; 20: 363–8. doi: https://doi.org/10.1002/eji.1830200220

80. Colgan SP, Reenstra WR, Morgan BP, et al. Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. Am J Physiol Cell Physiol 1999; 276–C450–C458. doi: https://doi.org/10.1152/ajpcell.1999.276.2.C450

81. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH, et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004; 114: 1098–106. doi: https://doi.org/10.1172/JCI200421086

82. Hatoum OA, Rinnion DG, Ottersen MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125: 58–69. doi: https://doi.org/10.1053/j.gastro.2003.06.030

83. Jaye DL, Parkos C. A. Neutrophil migration across intestinal epithelium. Ann N Y Acad Sci 2000; 915: 151–61. doi: https://doi.org/10.1111/j.1749-6632.2000.tb05288.x

84. King PD, Batchelor AH, Lawlor P, Katz DR. The role of CD44, CD45, CD45RO, CD46 and CD55 as potential anti-adhesion molecules involved in the binding of human tonsillar T cells to phorbol 12-myristate 13-acetate-differentiated U-937 cells. Eur J Immunol 1990; 20: 363–8. doi: https://doi.org/10.1002/eji.1830200220
97. Louis NA, Hamilton KE, Tong T, Colgan SP. HIF-dependent induction of apical CD55 coordinates epithelial clearance of neutrophils. *FASEB J* 2005; 19: 950–9. doi: https://doi.org/10.1096/fj.04-3251com

98. Bulla R, Tripodo C, Rami D, Ling GS, Agostinis C, Guarinotta C, et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. *Nat Commun* 2016; 7: 10346. doi: https://doi.org/10.1038/ncomms10346

99. Mold C, Morris CA. Complement activation of intracellular reactive oxygen species, hypoxic human endothelial cells: role activation following reoxygenation of vein endothelial cells activates the classic complement pathway. *Circulation* 1997; 96: 326–33. doi: https://doi.org/10.1161/01.CIR.96.1.326

100. Collard CD, Vakeva A, Bukusoglu C, Zund G, Sperati CJ, Colgan SP, et al. Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. *Circulation* 1997; 96: 326–33. doi: https://doi.org/10.1161/01.CIR.96.1.326

101. Collard CD, Agha A, Stahl GL. Complement activation following reoxygenation of hypoxic human endothelial cells: role of intracellular reactive oxygen species, NF-κB and new protein synthesis. *Immunopharmacology* 1998; 39: 39–50. doi: https://doi.org/10.1016/S0162-3109(97)00096-9

102. Taylor RP, Lindorfer MA. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies. *Semin Immunol* 2016; 28: 309–16. doi: https://doi.org/10.1016/j.smim.2016.03.003

103. Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius M. Complement in antibody-based tumor therapy. *Crit Rev Immunol* 2014; 34: 199–214. doi: https://doi.org/10.1615/CritRevImmunol.201409761

104. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. *Blood* 1994; 83: 435–45.

105. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody to CD20. *Blood* 1994; 83: 435–45.

106. Karsten CM, Köhl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. *Immunobiology* 2012; 217: 1067–79. doi: https://doi.org/10.1016/j.imbio.2012.07.015

107. Karsten CM, Köhl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. *Immunobiology* 2012; 217: 1067–79. doi: https://doi.org/10.1016/j.imbio.2012.07.015

108. Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, et al. A Combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis. *Cancer Discov* 2017; 7: 694–703. doi: https://doi.org/10.1158/2159-8290.CD-16-1184

109. Surace L, Lysenko V, Fontana AO, Cecconi V, Jansen H, Bivcic A, et al. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. *Immunology* 2015; 42: 767–77. doi: https://doi.org/10.1016/j.immun.2015.03.009

110. Elvington M, Scheiber M, Yang X, Lyons K, Jacqmin D, Wadsworth C, et al. Complement-dependent modulation of antitumor immunity following radiation therapy. *Cell Rep* 2014; 8: 818–30. doi: https://doi.org/10.1016/j.celrep.2014.06.051

111. Boire A, Zou Y, Shieh J, Macalinoa DG, Pentsova E, Massagüé J, et al. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. *Cell* 2017; 168: 1101–13. doi: https://doi.org/10.1016/j.cell.2017.02.025

112. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JJ, Cheng P, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. *J Exp Med* 2010; 207: 2439–53. doi: https://doi.org/10.1084/jem.20100587

113. Dan G, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F, et al. Hypoxia-inducible factor-1α promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. *Cancer Res* 2006; 66: 1684–93. doi: https://doi.org/10.1158/0008-5472.CAN-05-2887

114. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. *Nat Rev Cancer* 2011; 11: 393–410. doi: https://doi.org/10.1038/nrc3064